Estimating renal impairment and evaluating antiretroviral dose adjustments among HIV-positive patients: a comparison of three hospitals by K Mackie et al.
BioMed Central
Journal of the International AIDS 
Society
ssOpen AccePoster presentation
Estimating renal impairment and evaluating antiretroviral 
dose adjustments among HIV-positive patients: a comparison of 
three hospitals
K Mackie1, R Weston2, S Sonecha*3, A Murungi3 and A Duncan4
Address: 1Alfred Hospital, Melbourne, Australia, 2Imperial College Healthcare NHS Trust, London, UK, 3Chelsea and Westminster NHS 
Foundation Trust, London, UK and 4Alfred Hospital, Melbourne, UK
* Corresponding author    
Purpose of the study
As HIV-positive patients are now surviving longer, they
are exposed to an increasing number of risk factors for
chronic renal failure (CRF) including HIV itself, aging and
co-morbidities such as hypertension, diabetes and vascu-
lar disease. This necessitates an increased awareness of
potential CRF by both HIV clinicians and pharmacists
[1,2].
The purpose of this study was to estimate prevalence of
renal impairment in a randomly selected group of HIV-
infected patients at three hospital outpatient clinics (one
Melbourne, two London) and to analyse antiretroviral
(ARV) dosing in those patients found to have renal
impairment; by comparing published dosing recommen-
dations with actual dosing.
Methods
Patients were selected randomly from outpatient ARV pre-
scriptions dispensed in pharmacy. Two serum creatinine
samples taken at least 6 months apart were reviewed for
each patient. Creatinine clearance (CrCl) was estimated
firstly using the Modification of Diet in Renal Disease for-
mula (eGFR). Patients with an eGFR of <60 mL/min were
reviewed further by estimating CrCl using the Cockcroft-
Gault (CG) formula. Patients with both CG CrCl measure-
ments <50 mL/min, which may require ARV dosage
adjustment, were checked against pharmacy dispensing
records to see if the appropriate dose had been prescribed.
Summary of results
Patient cohorts included Alfred Hospital (n = 200), St
Mary's Hospital (n = 225) and Chelsea & Westminster
Hospital (C&W, n = 197). Total number of patients
included was 622. Results showed that overall 21 (3.4%)
and 19 (3.1%) patients had a CrCl of <60 mL/min using
eGFR and CG, respectively. Dosage adjustments were
required in 13 patients, but were only made in five
patients. Antiretrovirals concerned included lamivudine,
emtricitabine and tenofovir. Of the eight patients who
failed to have dosage adjustments made, seven were tak-
ing a combination product, either Truvada® or Kivexa®.
Some patients were on more than one ARV drug requiring
dose adjustment. (Tables 1 and 2.)
Conclusion
Although eGFR is now clinically regarded as the new
standard for measuring renal impairment, dose adjust-
ment recommendations for ARV drugs are based on CG
estimates. With the introduction of fixed dose combina-
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Table 1: Patient demographics.
Alfred St Marys C&W
Number of patients 200 225 197
Median age in years (range) 46 (22–81) 42 (17–76) 45 (18–76)
Male (%) 184 (92) 175 (78) 173 (88)
Race: non-Black (%) 196 (98) 154 (68.4) 169 (85.8)Page 1 of 2
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tions, pharmacists should be aware that drug dose adjust-
ment may require use of individual drugs and liquid
formulations. Further work needs to be undertaken in
individual units to develop a system for identifying
patients who require careful renal monitoring and subse-
quent dosage adjustment. The result of not adjusting
doses when required needs to be studied.
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Table 2: Results.
Alfred St Marys C&W Overall
Number of patients 200 225 197 622
eGFR <60 mL/min/1.73 m2 7 (3.5%) 6 (2.7%) 8 (4.1%) 21 (3.4%)
CG <60 mL/min 5 (2.5%) 6 (2.7%) 8 (4.1%) 19 (3.1%)
CG <50 mL/min requires ARV dose adjustment 5 (2.5%) 3 (1.3%) 5 (2.5%) 13 (2.1%)
Number of patients prescribed correct adjusted ARV dose if required 3 (60%) 1 (33%) 1 (20%) 5 (38%)
No. of patients on lamivudine requiring dose adjustment 5 (2 adjusted) 1 (0 adjusted) 3 (0 adjusted) 9 (2 adjusted)
No. of patients on emtricitabine requiring dose adjustment 0 1 (0 adjusted) 2 (1 adjusted) 3 (1 adjusted)
No. of patients on tenofovir requiring dose adjustment 2 (2 adjusted) 2 (1 adjusted) 2 (1 adjusted) 6 (4 adjusted)Page 2 of 2
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